Focusing on AD pathology, both the accumulation of amyloid-β (Aβ) in plaques and aggregation of the protein tau in neurofibrillary tangles are biomarkers that can be used to monitor the progression of AD (Jack et al., 2016). This evidence concerns the gene MAPT and Alzheimer disease.